- Home
- EXEL vs LII Comparison
EXEL vs LII Comparison
Compare EXEL & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | LII |
|---|---|---|
| Founded | 1994 | 1895 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 15.2B |
| IPO Year | 2000 | 1999 |
Fundamental Metrics
Financial Performance| Metric | EXEL | LII |
|---|---|---|
| Price | $70.52 | $352.27 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 18 |
| Target Price | $59.79 | ★ $371.92 |
| AVG Volume (30 Days) | ★ 2.3M | 659.5K |
| Earning Date | 10-29-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 1.58% |
| EPS Growth | ★ 57.95 | N/A |
| EPS | 2.46 | ★ 17.47 |
| Revenue | $452,477,000.00 | ★ $5,195,300,000.00 |
| Revenue This Year | $10.16 | $5.73 |
| Revenue Next Year | $12.43 | $5.59 |
| P/E Ratio | $28.34 | ★ $19.73 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $37.58 | $322.00 |
| 52 Week High | $72.10 | $587.27 |
Technical Indicators
Market Signals| Indicator | EXEL | LII |
|---|---|---|
| Relative Strength Index (RSI) | 83.32 | 45.42 |
| Support Level | $54.85 | $347.06 |
| Resistance Level | N/A | $377.56 |
| Average True Range (ATR) | 1.80 | 13.74 |
| MACD | 0.59 | -0.54 |
| Stochastic Oscillator | 87.36 | 49.63 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About LII Lennox International Inc.
Lennox manufactures and distributes heating, ventilating, air conditioning, and refrigeration products for the North American replacement (75% of sales) and new construction (25% of sales) markets. Residential HVAC (home comfort solutions) accounts for 67% of sales and commercial HVAC (building climate solutions) accounts for the remaining 33% of sales. Lennox's commercial exposure is what its peers refer to as residential and light commercial, and lacks the scale and complexity of what is referred to as an applied solution. The company goes to market with multiple brands, but Lennox is its flagship HVAC brand.